Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Expanded access; Therapeutic Use
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 14 Mar 2018 Status changed from recruiting to completed.
- 12 Apr 2017 Status changed from not yet recruiting to recruiting.